Novo drug bests Byetta in ADA study

Amylin Pharmaceuticals' stock is suffering from a Novo Nordisk study that showed its experimental diabetes drug liraglutide outperformed Amylin's flagship drug Byetta, co-developed with Eli Lilly; shares dropped more than 8 percent Friday to close at $29.93. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.